ClinicalTrials.gov
public full text
Public Domain
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy regimen for metastatic disease, and in male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed systemic therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents#969224
- Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T#1112635
- Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression#837556
- IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer#848884
- An EORTC Study Updating the QLQ-BR23 to BR45#868088
Record · ID 800770
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive